- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04994002
A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations
A Phase 1b, Open-Label, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults (Aged 18-31 Years) With Complex Lymphatic Malformations
Study Overview
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Participants must fulfill the following requirements to be eligible for the study:
- Participant is 18 to 31 years of age (inclusive) at the time of consent.
- Participant has a verified diagnosis of a complex lymphatic malformation. Other moderate to severe vascular anomalies with associated lymphatic involvement will be considered, with approval by the study medical monitor.
- Participant's complex lymphatic malformation is considered, in the opinion of the investigator, to be moderate to severe.
Participant has adequate liver function defined as:
- Total bilirubin (sum of conjugated and unconjugated) ≤1.5 × upper limit of normal (ULN)
- Aspartate transaminase/Alanine aminotransferase (AST/ALT) <5 × ULN
- Serum albumin > 2 g/dL
- Participant has fasting low-density lipoprotein (LDL) of <160 mg/dL.
Participant has adequate bone marrow function defined as:
- Peripheral absolute neutrophil count (ANC) > 1000/µL
- Hemoglobin > 8.0 g/dL
- Platelet count ≥ 50,000/µL
Participant has adequate renal function defined as:
• Serum creatinine ≤ 1.5 mg/dL or calculated creatinine clearance of > 50 mL/min according to the Cockcroft-Gault equation
Participant has agreed to and met the washout period as follows:
- At least 14 days prior to initiation of CERC-006 if receiving sirolimus (also known as rapamycin), mitogen-activated protein kinase (MEK) inhibitors, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) inhibitors, interferon alfa 2b, vascular endothelial growth factor receptor 3 (VEGFR-3) inhibitors, and/or other systemic agents targeting lymphatic malformation
- At least 7 days prior to initiation of CERC-006 if receiving topical agents targeting lymphatic malformation
- Participant has a Karnofsky performance status of ≥50%.
Exclusion Criteria:
The presence of any of the following criteria excludes a participant from the study:
- Participant has a concurrent severe or uncontrolled medical disorder, which could compromise participation in the study.
- Participant has significant impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of CERC-006.
- Participant has taken any medication that is a strong cytochrome P450 3A4 (CYP3A4) enzyme inducer or inhibitor within 2 weeks prior to first dose of study drug, or in the opinion of the Investigator, subject may require such medication during the study
- Participant is receiving chronic treatment with systemic steroids or another immunosuppressive agent, or in the opinion of the Investigator, subject may require such medication during the study
- Participant has undergone myelosuppressive chemotherapy within 2 weeks, or radiation within 4 weeks prior to first dose of study drug.
- Participant has a known history of uncontrolled hypertension, cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, cardiac conduction problems, heart failure, exercise-related cardiac events including syncope and pre-syncope, or a known family history of sudden cardiac death or ventricular arrhythmia.
- Participant has received treatment with a medication that has the potential to prolong the QT interval within 1 week prior to the first dose of study drug, or in the opinion of the Investigator, subject may require such medication during the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1: CERC-006 (0.5 mg)
Approximately 5 participants will receive CERC-006 at a dose of 0.5 mg twice daily for 28 days.
|
Oral solution
|
Experimental: Cohort 2: CERC-006 (1 mg)
Following a safety review, if there are no clinically important safety findings in Cohort 1, a second cohort of approximately 5 participants will be enrolled to receive CERC-006 at a dose of 1 mg twice daily for 28 days.
|
Oral solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Tolerability of CERC-006 in Adults (Aged 18-31 Years) with Active, Moderate to Severe Complex Lymphatic Malformations
Time Frame: Up to approximately 6 weeks
|
Safety and tolerability will be assessed by incidence of adverse events (AEs).
Clinically significant changes from baseline in vital signs, ocular exams, cardiology tests including echocardiogram (ECHO) and electrocardiogram (ECG), and clinical laboratory results will be recorded as AEs.
|
Up to approximately 6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum Concentrations of CERC-006
Time Frame: Baseline (Day 1) up to 3 days after last dose of study drug (up to approximately 4 weeks)
|
Baseline (Day 1) up to 3 days after last dose of study drug (up to approximately 4 weeks)
|
|
Change from Baseline in Levels of mTOR Related Pathway Biomarkers
Time Frame: Baseline (Day 1) up to 3 days after last dose of study drug (up to approximately 4 weeks)
|
Baseline (Day 1) up to 3 days after last dose of study drug (up to approximately 4 weeks)
|
|
Change from baseline to end of treatment in radiologic assessment, if clinically indicated and/or clinical signs/symptoms of disease
Time Frame: Baseline (Screening) up to 3 days after last dose of study drug (up to approximately 8 weeks)
|
Radiologic disease assessment will be done if clinically indicated, at the discretion of the investigator.
|
Baseline (Screening) up to 3 days after last dose of study drug (up to approximately 8 weeks)
|
Change from Baseline in 36-Item Short Form Health Survey (SF-36) Score
Time Frame: Baseline (Day 1) up to 3 days after last dose of study drug (up to approximately 4 weeks)
|
SF-36 score will measure eight scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health.
Scores on each scale will be directly transformed into a 0-100 scale, where a lower score indicates more disability.
|
Baseline (Day 1) up to 3 days after last dose of study drug (up to approximately 4 weeks)
|
Change from Baseline in Karnofsky Performance Status Score
Time Frame: Baseline (Day 1) up to 3 days after last dose of study drug (up to approximately 4 weeks)
|
Karnofsky Performance Status score will be measured on a scale from 0 percent (%) to 100%, where a lower percentage score indicates a worse disease state.
|
Baseline (Day 1) up to 3 days after last dose of study drug (up to approximately 4 weeks)
|
Change from Baseline in Pain Scale Assessment
Time Frame: Baseline (Day 1) up to 3 days after last dose of study drug (up to approximately 4 weeks)
|
Pain scale assessment will be done using a 100 mm Visual Analog Scale (VAS) from no pain (0 mm) to extreme pain (100 mm).
|
Baseline (Day 1) up to 3 days after last dose of study drug (up to approximately 4 weeks)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CERC-006-LM-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphatic Malformation
-
Venthera, Inc., a BridgeBio companyTerminatedLymphatic Malformation | Venous Malformation | Venolymphatic MalformationUnited States
-
Murdoch Childrens Research InstituteRoyal Children's Hospital; Peter MacCallum Cancer Centre, AustraliaNot yet recruitingArteriovenous Malformations | Vascular Malformations | MAP2K1 Gene Mutation | PIK3CA-related Overgrowth Spectrum | Vascular Anomalies | Lymphangioma | Lymphatic Malformation | KRAS G12D | Venous Malformation | Vascular Anomaly | KRAS G12C | PI3K Gene Mutation | Slow-Flow Vascular Malformation | Fast-Flow Vascular... and other conditionsAustralia
-
Medical University of South CarolinaRecruiting
-
Sohag UniversityRecruitingVascular Malformations | Microcystic Lymphatic Malformation | Combined Vascular MalformationEgypt
-
Children's Hospital Medical Center, CincinnatiUnknownTufted Angioma | Microcystic Lymphatic Malformation | Kaposiform Hemangioendotheliomas | Capillary Venous Lymphatic Malformation | Venous Lymphatic Malformation | Mucocutaneous Lymphangiomatosis and Thrombocytopenia | Capillary Lymphatic Arterial Venous Malformations | PTEN Overgrowth Syndrome With... and other conditionsUnited States
-
Nanjing Children's HospitalRecruiting
-
Protara TherapeuticsRecruiting
-
Palvella Therapeutics, Inc.RecruitingMicrocystic Lymphatic MalformationUnited States
-
West China HospitalCompleted
-
Palvella Therapeutics, Inc.Not yet recruitingMicrocystic Lymphatic MalformationUnited States
Clinical Trials on CERC-006
-
Wave Life Sciences Ltd.RecruitingAlpha-1 Antitrypsin DeficiencyUnited Kingdom
-
Nitto BioPharma, Inc.Active, not recruitingColorectal Cancer | Pancreatic Cancer | Non-Small Cell Lung CancerUnited States
-
Corvus Pharmaceuticals, Inc.TerminatedCovid-19United States, Colombia, Spain, Canada, Peru, Brazil, Italy, Argentina, Chile, Germany, Mexico, Ukraine
-
eTheRNA immunotherapiesTerminated
-
Apollo Therapeutics LtdTerminatedAdult Onset Still's DiseaseUnited States, Belgium, Poland, Ukraine
-
Corvus Pharmaceuticals, Inc.CompletedSarcoma | Cervical Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Renal Cell Cancer | Non-hodgkin Lymphoma | Metastatic Castration Resistant Prostate...United States, Australia
-
Huahui HealthCompleted
-
Arixa PharmaceuticalsUnknown